ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program

- ICT-107 Protocol Amendment Being Implemented in US Clinical Sites; Amended Protocol Submissions Underway in Europe and Canada.
- Successful Sequencing of Target T Cell Receptor Gene is Key Step in Advancing toward Identification of Potential Clinical Candidate in Stem-to-T-Cell Program.
LOS ANGELES, March 6, 2017  -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) today provided an update on the Company's ICT-107 phase 3 registration trial in newly diagnosed glioblastoma, and announced advances in its Stem-to-T-cell Research program.
Read more: ImmunoCellular Therapeutics ( IMUC )

Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis

- Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF -
- Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments -
- Concert to Host Conference Call at 8:30 AM EST to Discuss Transaction and 2016 Financial Results -
LEXINGTON, Mass. --  Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) under which Vertex will acquire CTP-656. CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination regimens of CFTR modulators that treat the underlying cause of CF. 
Read more: Concert Pharmaceuticals ( CNCE )

TG Therapeutics Announces Positive Topline Data from Phase 3 GENUINE Study of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia (CLL)

Study met its primary endpoint, with TG-1101 (ublituximab) plus ibrutinib increasing Overall Response Rate (ORR) by >70% over ibrutinib alone
The combination was well tolerated with a safety profile consistent with the Phase 2 study of ublituximab plus ibrutinib recently published in the British Journal of Haematology
Targeting full data presentation at a medical meeting in 1H17 and meeting with FDA in 2H17 to discuss the results and filing for accelerated approval
Conference call to be held today, Monday March 6, 2017 at 8:30 am ET, with Dr. Anthony Mato from the University of Pennsylvania, a lead enroller in the GENUINE trial
NEW YORK, March 06, 2017 -- TG Therapeutics (NASDAQ:TGTX) today announced positive topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia (CLL).  For the study, high risk was defined as having any one or more of the following: 17p deletion, 11q deletion or p53 mutation.
Read more: TG Therapeutics ( TGTX )

NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson ’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting

- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) -
- The trial also showed statistically significant reduction in troublesome dyskinesia and a complete reduction of OFF-time to zero hours in 66% of responders (post hoc sub-groups analyses) -
REHOVOT, Israel, March 01, 2017 --  NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that a preliminary analysis of trial 006 demonstrated that the trial successfully met its primary, key secondary and additional secondary endpoints. Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease.
Read more: NeuroDerm Ltd ( NDRM )

BELLUS Health and The NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough

- Potential best-in-class drug candidate targeting the clinically validated P2X3 receptor for chronic cough -
- Potential to help millions of chronic cough patients, including those who do not respond to current therapies -
MONTREAL, Feb. 28, 2017 - BELLUS Health (TSX:BLU), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, and The NEOMED Institute (NEOMED), a not-for-profit organization bridging the gap between basic research and the commercialization of new drugs, today announced that BELLUS Health has obtained an exclusive worldwide license to develop and commercialize BLU-5937 (formerly NEO5937) for the treatment of chronic cough. BLU-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor.
Read more: BELLUS Health ( BLU )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker